After slicing and dicing TCRs for 8 years, Swedish biotech reloads to angle for a spot in crowded cell therapy space

Södertälje, Sweden, the historic home to the Astra half of AstraZeneca, may seem an unlikely place for cutting-edge R&D on T cell receptors and cell therapies. And Reagan Jarvis — a transplant from New Zealand who had spent his academic years studying innate immune signaling — readily admits he doesn’t...

Click to view original post